ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST Jan 6, 2024 03:59PM
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST Jan 1, 2024 12:35PM
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 5, 2023 07:00AM
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update Aug 10, 2023 07:35AM
Milestone Pharmaceuticals (MIST) Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet Jun 20, 2023 07:01AM
View Older Stories

Jun 20, 2023 07:00AM Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
Jun 1, 2023 07:00AM Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 22, 2023 07:00AM Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate
May 11, 2023 07:16AM Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update
May 8, 2023 07:00AM Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate
Apr 12, 2023 07:00AM Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Mar 29, 2023 09:17AM Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update
Mar 28, 2023 07:04AM Milestone Pharmaceuticals (MIST) Announces $125M Financing with RTW Investments
Mar 28, 2023 07:00AM Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT
Mar 6, 2023 07:00AM Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia
Feb 28, 2023 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 29, 2022 07:00AM Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
Nov 22, 2022 07:00AM Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Nov 10, 2022 07:21AM Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
Nov 7, 2022 12:13PM Milestone Pharmaceuticals (MIST) Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA
Nov 7, 2022 12:13PM Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022
Oct 25, 2022 07:00AM Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the Americ
Oct 17, 2022 06:00AM Milestone Pharmaceuticals (MIST) Reports Positive Results from Phase 3 RAPID Trial of Etripamil
Oct 17, 2022 06:00AM Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
Sep 6, 2022 07:00AM Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 10, 2022 04:15PM Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
Jun 2, 2022 07:00AM Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 27, 2022 05:03PM Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2022 07:00AM Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 12, 2022 07:15AM Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
Apr 30, 2022 09:00AM Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
Apr 15, 2022 04:41PM Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 14, 2022 07:00AM Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
Mar 24, 2022 07:20AM Milestone Pharmaceuticals Inc. (MIST) Reports Q4 Earnings, Provides Clinical and Corporate Update
Mar 24, 2022 07:20AM Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update
Mar 1, 2022 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 16, 2022 07:08AM Milestone Pharmaceuticals Inc. (MIST) Appoints David Bharucha as Chief Medical Officer
Feb 16, 2022 07:00AM Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
Jan 4, 2022 07:00AM Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Nov 15, 2021 07:00AM Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT
Nov 12, 2021 07:20AM Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
Nov 11, 2021 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Sep 22, 2021 07:00AM Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 7, 2021 07:00AM Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 11, 2021 04:18PM Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
May 26, 2021 07:00AM Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
May 17, 2021 07:03AM Milestone Pharmaceuticals (MIST) Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
May 17, 2021 07:02AM Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
May 17, 2021 07:01AM Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
May 17, 2021 07:00AM Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
Mar 30, 2021 06:09AM Milestone Pharmaceuticals Inc. (MIST) Reports First Patient Enrolled in ReVeRA Study, Phase 2 Trial of Etripamil in Atrial Fibrillation & Rapid Ventricular Rate
Mar 29, 2021 05:32PM Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corporate Update
Mar 29, 2021 05:30PM Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
Feb 25, 2021 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 23, 2020 07:00AM Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
View Older Stories